Pembrolizumab
Brand name: Keytruda
Rank #263 of 500 drugs by total cost
$46.9M
Total Cost
3,947
Total Claims
$46.9M
Total Cost
125
Prescribers
$12K
Cost per Claim
140
Beneficiaries
3,968
30-Day Fills
$375K
Avg Cost/Provider
32
Avg Claims/Provider
About Pembrolizumab
Pembrolizumab (sold as Keytruda) was prescribed 3,947 times by 125 Medicare Part D providers in 2023, costing the program $46.9M. At $12K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 260 | Cabotegravir/Rilpivirine (Cabenuva) | $48.1M | 7,384 |
| 261 | Cenobamate (Xcopri) | $47.6M | 33,831 |
| 262 | Clozapine (Clozapine) | $47.0M | 491,951 |
| 263 | Pembrolizumab (Keytruda) | $46.9M | 3,947 |
| 264 | Glipizide (Glipizide) | $46.9M | 2,961,035 |
| 265 | Losartan/Hydrochlorothiazide (Losartan-Hydrochlorothiazide) | $46.3M | 2,039,676 |
| 266 | Darunavir (Prezista) | $46.0M | 21,793 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology